Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
DoD Tuberous Sclerosis Complex, Clinical Translational Research Award
The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC.
Projects supported by this award mechanism may include, but are not limited to:· Studies moving
from preclinical to clinical research and/or the reverse, or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or improve diagnosis, prognosis, or treatment.
· Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics.
· Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action.
These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes.Preclinical studies may be appropriate but must include a clinical component.
Projects that are strictly animal research will not be considered for funding and should consider other FY23 TSCRP funding opportunities.
Projects supported by this award mechanism may include, but are not limited to:· Studies moving
from preclinical to clinical research and/or the reverse, or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or improve diagnosis, prognosis, or treatment.
· Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics.
· Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action.
These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes.Preclinical studies may be appropriate but must include a clinical component.
Projects that are strictly animal research will not be considered for funding and should consider other FY23 TSCRP funding opportunities.
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
Link to Opportunity in SAMS Domestic
Additional Information of Eligibility:
DRL welcomes applications from U.S.-based and foreign-based non-profit organizations/nongovernmental organizations (NGO) and public international organizations; private, public, or state institutions of higher education; and for-profit organizations or businesses.
DRL’s preference is to work with non-profit entities; however, there may be some occasions when a for-profit entity is best suited.
Full Opportunity Web Address:
https://mygrants.servicenowservices.com/grants?id=grants_funding_opportunity&table=u_domestic_funding_opportunity&sys_id=a0bff5c61b612d5000f2ea4ce54bcb88&view=Default
Contact:
Agency Email Description:
CDMRP Help Desk
Agency Email:
Date Posted:
2023-03-14
Application Due Date:
Archive Date:
2023-08-06
Social Entrepreneurship
Spotlight
Building a Million Dollar Company Where Everyone Counts
Ganesh Natarajan is the Founder and Chairman of 5FWorld, a new platform for funding and developing start-ups, social enterprises and the skills eco-system in India. In the past two decades, he has built two of India’s high-growth software services companies – Aptech and Zensar – almost from scratch to global success.
Learn How to Identify and Avoid Grant Scams
